Phase 2 Trial of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B

C

Chongqing Jiachen Biotechnology

Status and phase

Completed
Phase 2

Conditions

Chronic Hepatitis B

Treatments

Other: Placebo
Biological: εPA-44

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT00869778
71006.01

Details and patient eligibility

About

The purpose is to evaluate efficacy and safety of therapeutic Hepatitis B Virus(HBV) vaccine (mimogen-based) treatment in chronic hepatitis B patients and to explore the most effective dosage and provide the rational for optimal dosing schedule.

Full description

First stage(0-76 weeks): Eligible subjects are enrolled and assigned to 3 groups randomly in a 1:1:1 ratio: εPA-44 600μg group:Subcutaneous inject εPA-44 600μg at week 0, 4, 8, 12, 20, 28;Polyene Phosphatidylcholine Capsules will be taken orally beginning in week 28. εPA-44 900μg group:Subcutaneous inject εPA-44 900μg at week 0, 4, 8, 12, 20, 28;Polyene Phosphatidylcholine Capsules will be taken orally beginning in week 28. Placebo control group:Subcutaneous inject empty liposome at week 0, 4, 8, 12, 20, 28;Polyene Phosphatidylcholine Capsules will be taken orally beginning in week 28. The study cycle consists of screening and enrollment period (week -6-0), treatment period (week 0-28) and follow-up period (week 28-76). Second stage(76-144 weeks): In this follow-up stage the trial is open designed, and all the subjects completed the first stage study(0-76 weeks): Subjects with no virological response and no serological response in the first stage , and refuse to continue the this follow-up study, will be provided domestic Adefovir Dipivoxil for one year freely; Subjects with virological response but no serological response/with serological response but no virological response/neither virological nor serological response in the first stage, and be willing to continue the this follow-up study, will be treated by εPA-44 900 μg; Subjects with both virological and serological response, will be followed-up to 144 weeks with no Adefovir Dipivoxil or εPA-44 900 μg treatment. The definition of response is defined as below: Virological response: HBV DNA<2.93×10∧3IU/ml at 76 weeks; Serological response: serological conversion of HBeAg at 76 weeks.

Enrollment

360 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Aged 18-65 years, male or female
  2. Conforms to diagnosis standard of chronic hepatitis B according to"2005 Guideline for Prevention and Treatment of Hepatitis B", (with positive HBsAg for more than 6 months), and HBV-DNA more than 100000 copies/ml;HBeAg (+),HBsAb(-); Alanine aminotransferase(ALT) within 2 to 10 times of ULN (upper limit of normal)
  3. HLA-A2 positive
  4. Compensatory liver disease having following hematological and biochemical indicators:WBC≥3.5E+9/L; ANC≥1.5E+9/L; PLT≥80E+9/L; Hb≥110g/L; TBil≤1.5ULN; ALB ≥ lower limit of normal value; BUN (Urea)≤upper limit of normal value; Cr≤upper limit of normal value; prothrombin time(PT) elongation≤3 sec; Activated partial thromboplastin time(APTT) within normal value; Fasting blood glucose≤7.0mmol/L
  5. TSH within normal value
  6. AFP ≤20ng/ml
  7. Uses effective contraception for subject with child-bearing potential (including females and female partners of males)
  8. Understands and signs ICF approved by EC
  9. Willing to comply with the study procedures and complete the study

Exclusion criteria

  1. Antibody of HAV IgM, HCV, HDV IgM or HEV IgM is positive
  2. Antibody of CMV IgM, EBV IgM or HIV is positive
  3. Antinuclear antibody titer>1:160
  4. Hepatocarcinoma, suspected hepatocarcinoma or hepatic cirrhosis
  5. Has any of the following illnesses or has a severe disease inappropriate for participation in the study based on the investigator's judgment, such as: Cardiovascular system: instable or significant cardiovascular illness such as angina pectoris, heart attack of myocardial infarction, congestive heart failure, severe hypertension, significant arrhythmia or abnormal ECG etc.; Respiratory system: bronchiectasis, bronchial asthma, chronic obstructive pulmonary disease, respiratory failure, etc.; Endocrine, metabolism diseases: diabetes mellitus, uncontrolled thyroid diseases, etc.; Others: autoimmune disorder, active tuberculosis, malignancies (e.g.tumor), neuropathic or metal illness history,etc.
  6. Has used anti-HBV drug (Interferon, Lamivudine, Adefovir Dipivoxil, Entecavir and Telbivudine) and immunomodulator (Thymic peptide,etc ) 6 months prior to the administration of study medication
  7. Has participated in any other drug clinical investigations within the past 3 months
  8. Has allergy habitus or has suspected allergy to study drug
  9. Female who is in pregnancy, in lactation or planning to become pregnant during the course of the study
  10. Has a history of alcohol abuse (Alcohol consumption for more than 5 years, with daily consumption over 40g for males and over 20g for females) and known drug dependence
  11. Has a history of organ transplant (except external corneal transplantation and hair transplantation)
  12. Any other factors inappropriate for enrollment in the study or study completion in the view of the investigator

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

360 participants in 3 patient groups, including a placebo group

εPA-44 900μg
Experimental group
Description:
Inject εPA-44 900μg at week 0, 4, 8, 12, 20, 28.
Treatment:
Biological: εPA-44
εPA-44 600μg+Placebo 300μg
Experimental group
Description:
Inject εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.
Treatment:
Biological: εPA-44
Other: Placebo
Placebo 900μg
Placebo Comparator group
Description:
Inject Placebo 900μg at week 0, 4, 8, 12, 20, 28.
Treatment:
Other: Placebo

Trial contacts and locations

15

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems